Famotidine Injection, USP 20 mg per 2 mL
Product details
- Famotidine Injection, USP 20 mg per 2 mL
Company announcement
Fresenius Kabi is voluntarily recalling three lots of Famotidine Injection due to out-of-specification endotoxin results.
The recall is nationwide, affecting users in the United States.
Non-serious adverse events including chills, fever, and altered mental status have been reported for one lot.
Risk:
Elevated endotoxin levels can precipitate severe systemic reactions such as sepsis and septic shock. Severe responses may include inflammatory and life-threatening immune responses and death.
Impacted states: Nationwide
Products:
- Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2mL fill in a 2 mL vial
- Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2mL fill in a 2 mL vial
- Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2mL fill in a 2 mL vial
Contact
For more information, call (866) 716-2459 or email productcomplaint.USA@fresenius-kabi.com.
Related recalls
- Argatroban Injection 250 mg/2.5 mL (100 mg/mL)
- Brevital Sodium 500 mg/vial for Injection
- Glutathione Injection
- Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
- 0.9% Sodium Chloride Injection, USP, 100 mL
- Compounded Glutathione 200 mg/mL 30 mL multidose vial; Myer’s Cocktail 30 mL multidose vial; Tri-Immune Boost 30 mL multidose vial